CHO-K1/Dog GIPR Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0103E | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The gastric inhibitory polypeptide receptor (GIPR) is a class B G protein-coupled receptor that specifically binds glucose-dependent insulinotropic polypeptide (GIP). It is primarily distributed in pancreatic β-cells, adipocytes, bone cells, and the central nervous system. Its core function is to mediate the diverse physiological actions of GIP: in the pancreas, it stimulates glucose-dependent insulin secretion postprandially; in adipose tissue, it enhances lipid synthesis and storage; and in bone, it regulates bone formation and turnover. Thus, GIPR is a key receptor linking nutrient intake to energy storage. However, in type 2 diabetes, its insulinotropic effect is often blunted while its lipogenic action persists, making it a crucial target for novel “dual (GIPR/GLP-1R) agonists” that synergistically improve both blood glucose and body weight.
Screeningbio’s HEK293/Dog GIPR cell line overexpress GIPR and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Dog |
HGNC Symbol | GIPR |
Accession Number | XM_005616439.3 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The gastric inhibitory polypeptide receptor (GIPR) is a class B G protein-coupled receptor that specifically binds glucose-dependent insulinotropic polypeptide (GIP). It is primarily distributed in pancreatic β-cells, adipocytes, bone cells, and the central nervous system.
Its core function is to mediate the diverse physiological actions of GIP: in the pancreas, it stimulates glucose-dependent insulin secretion postprandially; in adipose tissue, it enhances lipid synthesis and storage; and in bone, it regulates bone formation and turnover. Thus, GIPR is a key receptor linking nutrient intake to energy storage.
However, in type 2 diabetes, its insulinotropic effect is often blunted while its lipogenic action persists, making it a crucial target for novel “dual (GIPR/GLP-1R) agonists” that synergistically improve both blood glucose and body weight.